August 17, 2011
Fuisz Pharma Announces Publication of US Patent Pending for a System That Confirms Drug Compliance
MIAMI, Aug. 17, 2011 /PRNewswire/ -- Fuisz Pharma (www.fuisz.com) today announced the publication of U.S. Patent Application US 20110182827 ("Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent").
This patent pending is directed towards a dosage form that includes a substance that is visible to a normal light or to a special light source in the buccal or vaginal cavity in order for medical personnel to confirm compliant use of a medication. The substance leaves behind a temporary stain for a predetermined period for compliance assessment.Joseph Matus Fuisz, Managing Member of Fuisz Pharma, stated, "This patent application sets forth a highly effective method of confirming compliant use of medications for the buccal or vaginal cavities. Its disclosure and claims are highly complimentary to the Gruber patent (US 7,214,385 "Pharmaceutical Formulation Containing Dye") previously acquired by Fuisz Pharma, which covers the use of a dye to show the misuse of an opioid dosage form, such as by snorting."
Noted inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz), together with Joseph Fuisz, is a named inventor on the announced patent application.
Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.
SOURCE Fuisz Pharma